Proteomics

Dataset Information

0

Non-canonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in cancer patients

ABSTRACT: ost characterized tumor antigens are ‘genomic’, i.e. encoded by canonical, non-canonical or somatically mutated genomic sequences. We investigate here the presentation and immunogenicity of tumor antigens derived from non-canonical mRNA splicing events between coding exons and transposable elements (TEs). Comparing non-small cell lung cancer (NSCLC), an immunogenic tumor type, and diverse non-tumor tissues, we identify several thousand splicing junctions between exons and diverse TE classes. A subset of these junctions is both tumor-specific and shared across patients. HLA-I peptidomic identifies peptides encoded by tumor-specific junctions in primary NSCLC samples and lung tumor cell lines. Recurrent junction-encoded peptides are immunogenic in vitro and CD8+ T cells specific for junction-encoded epitopes are present in tumors and tumor-draining lymph nodes from NSCLC patients. We conclude that non-canonical splicing junctions between exons and TEs represent a source of recurrent, immunogenic tumor-specific antigens in NSCLC cancer patients.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Yago Arribas  

LAB HEAD: Sebastian Amigorena

PROVIDER: PXD034820 | Pride | 2023-02-27

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
4064_MC_H1395-Fr0-10.raw Raw
4064_MC_H1395-Fr14-22.raw Raw
4064_MC_H1395-Fr26-34.raw Raw
4064_MC_H1650-Fr14-22.raw Raw
4376_MC_HP_1395.raw Raw
Items per page:
1 - 5 of 13
altmetric image

Publications

Although most characterized tumor antigens are encoded by canonical transcripts (such as differentiation or tumor-testis antigens) or mutations (both driver and passenger mutations), recent results have shown that noncanonical transcripts including long noncoding RNAs and transposable elements (TEs) can also encode tumor-specific neo-antigens. Here, we investigate the presentation and immunogenicity of tumor antigens derived from noncanonical mRNA splicing events between coding exons and TEs. Co  ...[more]

Similar Datasets

Genomics Epigenetically-controlled tumor antigens derived from splice junctions between exons and transposable elements
| PRJNA902299 | ENA
Genomics Epigenetically-controlled tumor antigens derived from splice junctions between exons and transposable elements [RNA-seq]
| PRJNA859788 | ENA
Genomics Epigenetically-controlled tumor antigens derived from splice junctions between exons and transposable elements [ChIP-seq]
| PRJNA860111 | ENA
Proteomics non-canonical HLA peptides in cancer
2020-03-27 | PXD013649 | Pride
Proteomics Proteogenomic Discovery of Neoantigens Facilitates Personalized Multi-antigen Targeted T cell Immunotherapy for Brain Tumors
2021-11-02 | PXD029082 | Pride
Proteomics Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinoma
2021-08-23 | PXD022949 | Pride
Proteomics NeoDisc: A neoantigen discovery pipeline for the development of personalized cancer immunotherapy
2024-08-30 | PXD047641 | Pride
Transcriptomics Immunogenic Senescence Sensitizes Lung Cancer to LUNX-Targeting Therapy [NCI-H292]
2024-10-03 | GSE185208 | GEO
Transcriptomics Immunogenic Senescence Sensitizes Lung Cancer to LUNX-Targeting Therapy [A549]
2024-10-03 | GSE185207 | GEO
Proteomics Using long-read CAGE sequencing to profile cryptic-promoter derived transcripts and their contribution to the immunopeptidome
2023-09-23 | PXD040265 | Pride